These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 7539179

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y.
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [Abstract] [Full Text] [Related]

  • 4. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, Opsomer R, Wese FX.
    Prostate Suppl; 1996 Jul; 7():30-4. PubMed ID: 8950361
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X, Alcover J, Corral JM, Molina R, Beardo P, Ballesta AM.
    Anticancer Res; 2001 Jul; 21(5):3717-20. PubMed ID: 11848550
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM, Boeckmann W, Effert PJ, Habib FK, Jakse G.
    Anticancer Res; 1997 Jul; 17(4B):2993-4. PubMed ID: 9329583
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J, Millet C, Levillain P, Doré B, Bégon F, Aubert J.
    Chirurgie; 1997 Jul; 122(8-9):478-82. PubMed ID: 9616891
    [Abstract] [Full Text] [Related]

  • 12. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F, Martínez M, Royo M, Vera CD, Estellés A, Aznar J, Jiménez-Cruz JF.
    Eur Urol; 1997 Jul; 32(3):268-72. PubMed ID: 9358211
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J, Haapalainen T, Punnonen K, Penttilä I.
    Anticancer Res; 2002 Jul; 22(1A):415-20. PubMed ID: 12017325
    [Abstract] [Full Text] [Related]

  • 18. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
    Hall MC, Roehrborn CG, McConnell JD.
    Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
    [Abstract] [Full Text] [Related]

  • 19. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F.
    Ann Clin Lab Sci; 2003 Aug; 33(3):320-3. PubMed ID: 12956448
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.